325 related articles for article (PubMed ID: 36762937)
1. Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets.
Morse JW; Rios M; Ye J; Rios A; Zhang CC; Daver NG; DiNardo CD; Zhang N; An Z
Expert Opin Investig Drugs; 2023 Feb; 32(2):107-125. PubMed ID: 36762937
[TBL] [Abstract][Full Text] [Related]
2. The past and future of CD33 as therapeutic target in acute myeloid leukemia.
Laszlo GS; Estey EH; Walter RB
Blood Rev; 2014 Jul; 28(4):143-53. PubMed ID: 24809231
[TBL] [Abstract][Full Text] [Related]
3. An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia.
Venugopal S; Daver N; Ravandi F
Curr Hematol Malig Rep; 2021 Feb; 16(1):89-96. PubMed ID: 33630233
[TBL] [Abstract][Full Text] [Related]
4. Investigational CD33-targeted therapeutics for acute myeloid leukemia.
Walter RB
Expert Opin Investig Drugs; 2018 Apr; 27(4):339-348. PubMed ID: 29534618
[TBL] [Abstract][Full Text] [Related]
5. The role of CD33 as therapeutic target in acute myeloid leukemia.
Walter RB
Expert Opin Ther Targets; 2014 Jul; 18(7):715-8. PubMed ID: 24750020
[TBL] [Abstract][Full Text] [Related]
6. CD33 directed bispecific antibodies in acute myeloid leukemia.
Clark MC; Stein A
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101224. PubMed ID: 33279180
[TBL] [Abstract][Full Text] [Related]
7. Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.
Han YC; Kahler J; Piché-Nicholas N; Hu W; Thibault S; Jiang F; Leal M; Katragadda M; Maderna A; Dushin R; Prashad N; Charati MB; Clark T; Tumey LN; Tan X; Giannakou A; Rosfjord E; Gerber HP; Tchistiakova L; Loganzo F; O'Donnell CJ; Sapra P
Clin Cancer Res; 2021 Jan; 27(2):622-631. PubMed ID: 33148666
[TBL] [Abstract][Full Text] [Related]
8. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.
Liu Y; Wang S; Schubert ML; Lauk A; Yao H; Blank MF; Cui C; Janssen M; Schmidt C; Göllner S; Kleist C; Zhou F; Rahfeld JU; Sauer T; Schmitt M; Müller-Tidow C
Int J Cancer; 2022 Apr; 150(7):1141-1155. PubMed ID: 34766343
[TBL] [Abstract][Full Text] [Related]
9. CD33-Targeted Therapies: Beating the Disease or Beaten to Death?
Maakaron JE; Rogosheske J; Long M; Bachanova V; Mims AS
J Clin Pharmacol; 2021 Jan; 61(1):7-17. PubMed ID: 32875599
[TBL] [Abstract][Full Text] [Related]
10. Emerging antibody-based therapies for the treatment of acute myeloid leukemia.
Angenendt L; Mikesch JH; Schliemann C
Cancer Treat Rev; 2022 Jul; 108():102409. PubMed ID: 35605472
[TBL] [Abstract][Full Text] [Related]
11. Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?
Rashidi A; Walter RB
Expert Rev Hematol; 2016; 9(4):335-50. PubMed ID: 26778118
[TBL] [Abstract][Full Text] [Related]
12. Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulations.
Patel SA; Bello E; Wilks A; Gerber JM; Sadagopan N; Cerny J
Leuk Res; 2023 Nov; 134():107388. PubMed ID: 37729719
[TBL] [Abstract][Full Text] [Related]
13. Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin.
Cowan AJ; Laszlo GS; Estey EH; Walter RB
Front Biosci (Landmark Ed); 2013 Jun; 18(4):1311-34. PubMed ID: 23747885
[TBL] [Abstract][Full Text] [Related]
14. Novel monoclonal antibody-based therapies for acute myeloid leukemia.
Morsink LM; Walter RB
Best Pract Res Clin Haematol; 2019 Jun; 32(2):116-126. PubMed ID: 31203993
[TBL] [Abstract][Full Text] [Related]
15. Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future.
Gottardi M; Sperotto A; Ghelli Luserna Di Rorà A; Padella A; Cangini D; Giannini MB; Simonetti G; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):395-410. PubMed ID: 32955828
[TBL] [Abstract][Full Text] [Related]
16. FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia.
Jen EY; Ko CW; Lee JE; Del Valle PL; Aydanian A; Jewell C; Norsworthy KJ; Przepiorka D; Nie L; Liu J; Sheth CM; Shapiro M; Farrell AT; Pazdur R
Clin Cancer Res; 2018 Jul; 24(14):3242-3246. PubMed ID: 29476018
[TBL] [Abstract][Full Text] [Related]
17. Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts.
Walter RB; Boyle KM; Appelbaum FR; Bernstein ID; Pagel JM
Blood; 2008 May; 111(9):4813-6. PubMed ID: 18326813
[TBL] [Abstract][Full Text] [Related]
18. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults.
Goldenson BH; Goodman AM; Ball ED
Expert Opin Biol Ther; 2021 Jul; 21(7):849-862. PubMed ID: 32990476
[TBL] [Abstract][Full Text] [Related]
19. LILRB4-targeting Antibody-Drug Conjugates for the Treatment of Acute Myeloid Leukemia.
Anami Y; Deng M; Gui X; Yamaguchi A; Yamazaki CM; Zhang N; Zhang CC; An Z; Tsuchikama K
Mol Cancer Ther; 2020 Nov; 19(11):2330-2339. PubMed ID: 32879051
[TBL] [Abstract][Full Text] [Related]
20. IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML.
Kovtun Y; Noordhuis P; Whiteman KR; Watkins K; Jones GE; Harvey L; Lai KC; Portwood S; Adams S; Sloss CM; Schuurhuis GJ; Ossenkoppele G; Wang ES; Pinkas J
Mol Cancer Ther; 2018 Jun; 17(6):1271-1279. PubMed ID: 29588393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
